James W. Janetka

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

Sonya Zabludoff, Chun Deng, Michael Grondine et al. · Molecular Cancer Therapeutics · 2008 · 410 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist

Caitlin N. Spaulding, Roger D. Klein, Ségolène Ruer et al. · Nature · 2017 · 324 citations

Life Sciences, Immunology, Infectious Diseases +5

Treatment and Prevention of Urinary Tract Infection with Orally Active FimH Inhibitors

Corinne K. Cusumano, Jerome S. Pinkner, Zhenfu Han et al. · Science Translational Medicine · 2011 · 312 citations · Full text

Medicine, Pharmacology, Urology +4

MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A

Agostinho G. Rocha, Antonietta Franco, Andrzej M. Krezel et al. · Science · 2018 · 252 citations

Life Sciences, Neurobiology, Neuroscience +17

Structure-Based Drug Design and Optimization of Mannoside Bacterial FimH Antagonists

Zhenfu Han, Jerome S. Pinkner, Bradley Ford et al. · Journal of Medicinal Chemistry · 2010 · 234 citations

Pharmacy, Medicinal Chemistry, Pharmacology +14